HPCTC conducts early-stage clinical pharmacology studies in healthy volunteers and proof of concept studies in a range of patient populations and is the largest commercial clinical research unit in North Carolina.
According to the company, the expanded service offering comes in response to an increasing demand from the pharmaceutical industry to understand the pharmacokinetic impact of novel drugs in renally compromised patients.
Additionally, HPCTC has contacted local nephrologists who will contribute to medical oversight and patient management.
In February of last year, the company also partnered with Verified Clinical Trials to help prevent duplicate enrollment in trials.